Among mice immunized with HYLSSILRL or SYLLGSGEARL (derived from Hspg2), about 50% of the immunized mice were able to reject the tumor completely but the activity was not significant because of a high variation in tumor rejection. Here, HSPG2 is linked to neoplasm.